Singular Genomics Systems, Inc. (NASDAQ:OMIC) CEO Buys $17,821.88 in Stock

Singular Genomics Systems, Inc. (NASDAQ:OMICGet Free Report) CEO Andrew Spaventa acquired 43,468 shares of the stock in a transaction dated Thursday, November 16th. The shares were purchased at an average price of $0.41 per share, for a total transaction of $17,821.88. Following the completion of the purchase, the chief executive officer now directly owns 3,986,206 shares in the company, valued at $1,634,344.46. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Singular Genomics Systems Stock Performance

OMIC traded down $0.03 on Monday, reaching $0.41. The company had a trading volume of 576,773 shares, compared to its average volume of 328,996. Singular Genomics Systems, Inc. has a fifty-two week low of $0.31 and a fifty-two week high of $3.00. The stock has a market cap of $29.75 million, a P/E ratio of -0.32 and a beta of 0.98. The company’s fifty day moving average is $0.39 and its 200 day moving average is $0.65. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.15 and a current ratio of 13.64.

Analyst Ratings Changes

Separately, The Goldman Sachs Group decreased their price target on shares of Singular Genomics Systems from $1.15 to $1.00 and set a “neutral” rating on the stock in a research note on Thursday, August 10th.

Get Our Latest Report on Singular Genomics Systems

Institutional Trading of Singular Genomics Systems

A number of institutional investors have recently bought and sold shares of the business. American International Group Inc. boosted its holdings in Singular Genomics Systems by 11.6% in the 2nd quarter. American International Group Inc. now owns 26,094 shares of the company’s stock valued at $100,000 after purchasing an additional 2,706 shares during the period. ProShare Advisors LLC boosted its holdings in Singular Genomics Systems by 27.6% in the 1st quarter. ProShare Advisors LLC now owns 16,289 shares of the company’s stock valued at $103,000 after purchasing an additional 3,521 shares during the period. Nuveen Asset Management LLC boosted its holdings in Singular Genomics Systems by 2.4% in the 3rd quarter. Nuveen Asset Management LLC now owns 238,869 shares of the company’s stock valued at $597,000 after purchasing an additional 5,665 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Singular Genomics Systems by 4.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 150,363 shares of the company’s stock valued at $302,000 after purchasing an additional 5,825 shares during the period. Finally, Morgan Stanley boosted its holdings in Singular Genomics Systems by 6.5% in the 4th quarter. Morgan Stanley now owns 108,937 shares of the company’s stock valued at $219,000 after purchasing an additional 6,620 shares during the period. Institutional investors own 55.75% of the company’s stock.

About Singular Genomics Systems

(Get Free Report)

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.

See Also

Receive News & Ratings for Singular Genomics Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Singular Genomics Systems and related companies with MarketBeat.com's FREE daily email newsletter.